


In response to the Office Action dated January 10, 2008 (Paper No. 20080104), please amend the above-identified application as follows:

a.) Amendment to the Claims

Claims 1-10 (Cancelled).

11. (Currently Amended) A benzoyl compound represented by general formula (IA):



[wherein

nA represents an integer of 1 to 5;

R^{1A} represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxy carbonyl, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, CONR⁷R⁸ (wherein R⁷ and R⁸ independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclic alkyl, or substituted or unsubstituted aryl, or R⁷

and R⁸ form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or NR⁹R¹⁰ (wherein R⁹ and R¹⁰ have the same meanings as the above R⁷ and R⁸, respectively);

R^{2A} represents substituted or unsubstituted aryl;

R^{3A} and R^{5A} R^{3A}, R^{4A} and R^{5A} each represent a hydrogen atom; and

R^{4A} represents a hydrogen atom; and

R^{6A} represents ~~a hydrogen atom~~, halogen, lower alkyl or aryl; ~~provided that~~

when R^{6A} is a hydrogen atom, and $-(CH_2)_nR^{1A}$ is

(a) 2 (acetoxymethyl)heptyl, 3-oxopentyl or pentyl;

R^{2A} is not 6-hydroxy-4-methoxy-3-methoxycarbonyl-2-pentylphenyl;

(b) 3-oxopentyl;

R^{2A} is not a group selected from the group consisting of 3-benzyloxycarbonyl-6-hydroxy-4-methoxy-2-pentylphenyl and 3-carboxy-6-hydroxy-4-methoxy-2-pentylphenyl; and

(c) n-propyl;

~~R^{2A} is not 2,4-dihydroxy-6-[(4-hydroxy-2-oxopyran-6-yl)methyl]phenyl,~~

or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) The benzoyl compound according to claim 11, wherein R^{2A} is substituted aryl having 1 to 3 substituents, or aryl, or a pharmaceutically acceptable salt thereof.

Claims 13 and 14 (Cancelled).

15. (Previously Presented) The benzoyl compound according to claim 11 or 12, wherein R^{1A} is CONR⁷R⁸, or a pharmaceutically acceptable salt thereof.

16. (Previously Presented) The benzoyl compound according to claim 11 or 12, wherein R^{6A} is lower alkyl, or a pharmaceutically acceptable salt thereof.

17. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, the benzoyl compound according to claim 16 or a pharmaceutically

acceptable salt of said benzoyl compound, together with a pharmaceutically acceptable carrier.

Claims 18-31 (Cancelled).

32. (Previously Presented) The benzoyl compound according to claim 11, wherein


nA is 1,

R^{1A} is $CONR^{7a}R^{8a}$ (wherein R^{7a} and R^{8a} independently represent lower alkyl substituted by hydroxyl or lower alkoxy), and

R^{6A} is lower alkyl,

or a pharmaceutically acceptable salt thereof.


33. (Previously Presented) The benzoyl compound according to claim



32, wherein R^{2A} is

(wherein R^{2a} represents substituted or unsubstituted lower alkoxy, and R^{2b} represents substituted or unsubstituted heterocyclic-alkyl oxy), or a pharmaceutically acceptable salt thereof.


34. (Previously Presented) The benzoyl compound according to claim



32, wherein R^{2A} is

(wherein R^{2a} represents substituted or unsubstituted lower alkoxy, and R^{2b} represents substituted or unsubstituted heterocyclic-alkyl oxy), or a pharmaceutically acceptable salt thereof.

35. (Previously Presented) The benzoyl compound according to claim



32, wherein R^{2A} is

(wherein R^{2b1} represents substituted or unsubstituted morpholino or substituted or unsubstituted piperidino), or a pharmaceutically acceptable salt thereof.